Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?

RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA talks.

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.

Assessing Recursion Pharmaceuticals (RXRX) After A 58% One-Year Share Price Decline

If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful ...
i-SCOOP

Recursive self improvement, AI that makes itself better

Discover the world of Recursive Self-Improvement (RSI) in AI. From I.J. Good's intelligence explosion to modern self-healing code and clinical applications, explore who is developing it, how it works, ...
Zacks Investment Research on MSN

Recursion Pharmaceuticals (RXRX) falls more steeply than broader market: What investors need to know

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.85, moving -3.27% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.33%. On ...
Nasdaq

Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...
The Globe and Mail

Is Recursion Pharmaceuticals a Meme Stock?

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...